サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1635623

緑内障：7市場の医薬品の予測と市場の分析 - 更新版

Glaucoma: Seven-Market Drug Forecast and Market Analysis - Update

出版日
発行
GlobalData
ページ情報
英文 108 Pages
納期
即納可能 即納可能とは
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=143.57円
緑内障：7市場の医薬品の予測と市場の分析 - 更新版
出版日: 2024年12月23日
発行: GlobalData
ページ情報: 英文 108 Pages
納期: 即納可能 即納可能とは
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

主要7市場全体の緑内障治療薬の市場規模は、2023年に21億米ドルと推定されました。市場は2033年までに約25億米ドルに達すると予測され、CAGRで2.1%の成長が見込まれます。

予測期間における緑内障市場の主な成長促進要因は以下の通りです。

  • 高齢化により、主要7市場全体で緑内障の有病率の増加が予測されています。
  • 米国と日本における6つのパイプライン薬品の上市
  • 緑内障治療のアンメットニーズへの対応が見込まれる新製品の上市

予測期間の緑内障市場の成長を抑制する主な障壁は以下の通りです。

  • 予測期間に複数の製品が独占販売権を失う予定であり、それに伴うジェネリック医薬品の浸食が成長の大きな障害となります。
  • 治療へのアドヒアランスの悪さが、予測期間を通じて緑内障の局所療法の売上を阻害し続けます。
  • 緑内障市場は混雑しており、ジェネリック化が進んでいるため、新治療薬の競合が激しいです。

当レポートでは、緑内障の主要7市場（米国、欧州5ヶ国、日本）について調査し、疾患の概要、市場の収益と予測、パイプラインの分析、現在と将来の競合の分析などを提供しています。

目次

第1章 緑内障：エグゼクティブサマリー

  • 緑内障市場は2023年～2033年に拡大します。
  • 新たなMOAまたは投与経路を持つ薬剤の開発は、緑内障の企業戦略の転換を意味します。
  • 特に患者のコンプライアンスの向上に関して、緑内障にはアンメットニーズが残っています。
  • 緑内障市場に参入する後期段階のパイプライン薬品が成長を促進する見通しです。
  • 医師の考え

第2章 イントロダクション

第3章 疾患の概要

  • 病因と病態生理学
    • 概要
    • 病因
    • NTG
    • 病態生理学
  • 分類/病期分類システム

第4章 疫学

  • 疾患の背景
  • 危険因子と併存疾患
  • 世界と過去の動向
  • 主要7市場の予測手法
  • 緑内障の疫学的予測（2023年～33年）
    • POAG（NTGを除く）の患者数
    • POAG（NTGを除く）の患者数：年齢別
    • POAG（NTGを除く）の患者数：性別
    • NTGの患者数
    • PACGの患者数
    • PACGの患者数：年齢別
    • PACGの患者数：性別
    • 急性/慢性PACGの患者数
    • 急性PACGの患者数
    • 続発性緑内障の患者数
  • 議論
    • 疫学的予測の考察
    • COVID-19の影響
    • 分析の限界
    • 分析の強み

第5章 疾病管理

  • 診断の概要
    • 眼底検査
    • 眼圧測定
    • 視野検査
    • 角膜厚測定
    • 隅角鏡検査
  • 治療の概要
    • 治療ガイドライン
  • 疾病管理に関するKOLの見解

第6章 現在の治療オプション

  • 概要

第7章 アンメットニーズと機会の評価

  • 概要
  • 患者のコンプライアンスの向上
  • より優れた眼圧低下能力を持つ治療法
  • 新しいドラッグデリバリーシステム
  • 神経保護薬
  • 診断とモニタリングの改良

第8章 研究開発戦略

  • 概要
    • 新しい眼圧降下薬
    • 緑内障におけるインプラント
  • 臨床試験の設計
    • 緑内障の臨床エンドポイント
    • 包含基準と除外基準

第9章 パイプライン評価

  • 概要
  • 臨床開発中の有望な医薬品

第10章 パイプライン評価の分析

  • 概要
  • 競合の評価

第11章 現在の企業と将来の企業

  • 概要
  • 取引の動向

第12章 市場見通し

  • 世界市場
    • 予測
    • 促進要因と障壁 - 世界（主要7市場）の問題
  • 米国
    • 予測
    • 主な出来事
    • 促進要因と障壁
  • 欧州5ヶ国
    • 予測
    • 主な出来事
    • 促進要因と障壁
  • 日本
    • 予測
    • 主な出来事
    • 促進要因と障壁

第13章 付録

図表

List of Tables

  • Table 1: Glaucoma: Key metrics in the 7MM
  • Table 2: The different causes of secondary glaucoma
  • Table 3: Classification of glaucoma by ICD-10 codes
  • Table 4: Classification of glaucoma by primary and secondary groups
  • Table 5: Classification of glaucoma by OAG and ACG sub-types
  • Table 6: Risk factors and comorbidities for glaucoma
  • Table 7: Diagnostic tests for glaucoma
  • Table 8: Ophthalmologic imaging techniques
  • Table 9: Treatment guidelines for glaucoma
  • Table 10: Top 10 deals by value, 2019-24
  • Table 11: Glaucoma market - global (7MM) drivers and barriers, 2023-33
  • Table 12: Key events impacting sales for glaucoma in the US, 2023-33
  • Table 13: Glaucoma market - drivers and barriers in the US, 2023-33
  • Table 14: Key events impacting sales for glaucoma in the 5EU, 2023-33
  • Table 15: Glaucoma market - drivers and barriers in the 5EU, 2023-33
  • Table 16: Key events impacting sales for glaucoma in Japan, 2023-33
  • Table 17: Glaucoma market - drivers and barriers in Japan, 2023-33
  • Table 18: High-prescribing physicians (non-KOLs) surveyed, by country

List of Figures

  • Figure 1: Global sales forecast by country for glaucoma in 2023 and 2033
  • Figure 2: Analysis of the company portfolio gap in glaucoma during the forecast period
  • Figure 3: Competitive assessment of the late-stage pipeline agents that GlobalData expects to be licensed for the treatment of glaucoma during the forecast period
  • Figure 4: The AqH flow in OAG and ACG
  • Figure 5: The AqH Cycle
  • Figure 6: 7MM, diagnosed prevalence of POAG (including NTG), both sexes, %, ages >=40 years, 2023
  • Figure 7: 7MM, diagnosed prevalence of POAG (excluding NTG), both sexes, %, ages >=40 years, 2023
  • Figure 8: 7MM, diagnosed prevalence of PACG, both sexes, %, ages >=40 years, 2023
  • Figure 9: 7MM, sources used and not used to forecast the diagnosed prevalent cases of POAG (excluding NTG)
  • Figure 10: 7MM, sources used to forecast the diagnosed prevalent cases of NTG
  • Figure 11: 7MM, sources used to forecast the diagnosed prevalent cases of PACG
  • Figure 12: 7MM, sources used to forecast the diagnosed incident cases of acute PACG
  • Figure 13: 7MM, sources used to forecast the diagnosed prevalent cases of secondary glaucoma
  • Figure 14: 7MM, diagnosed prevalent cases of POAG (excluding NTG), N, both sexes, ages >=40 Years, 2023
  • Figure 15: 7MM, diagnosed prevalent cases of POAG (excluding NTG) by age, N, both sexes, 2023
  • Figure 16: 7MM, diagnosed prevalent cases of POAG (excluding NTG) by sex, N, ages >=40 Years, 2023
  • Figure 17: 7MM, diagnosed prevalent cases of NTG, N, both sexes, ages >=40 years, 2023
  • Figure 18: 7MM, diagnosed prevalent cases of PACG, N, both sexes, ages >=40 years, 2023
  • Figure 19: 7MM, diagnosed prevalent cases of PACG by age, N, both sexes, 2023
  • Figure 20: 7MM, diagnosed prevalent cases of PACG by sex, N, both sexes, ages >=40 Years, 2023
  • Figure 21: 7MM, diagnosed prevalent cases of acute and chronic PACG, N, both sexes, ages >=40 years, 2023
  • Figure 22: 7MM, diagnosed incident cases of acute PACG, N, both sexes, ages >=40 years, 2023
  • Figure 23: 7MM, diagnosed prevalent cases of secondary glaucoma, N, both sexes, ages >=40 years, 2023
  • Figure 24: Unmet needs and opportunities in glaucoma
  • Figure 25: Overview of the development pipeline in glaucoma
  • Figure 26: Key late-stage trials for the promising pipeline agents that GlobalData expects be licensed for glaucoma in the 7MM during the forecast period
  • Figure 27: Competitive assessment of the promising pipeline agents that GlobalData expects to be licensed for glaucoma in the 7MM during the forecast period
  • Figure 28: Competitive assessment of the marketed and pipeline drugs benchmarked against the SOC, latanoprost
  • Figure 29: Analysis of the company portfolio gap in glaucoma during the forecast period
  • Figure 30: Global (7MM) sales forecast by country for glaucoma in 2023 and 2033
  • Figure 31: Sales forecast by class for glaucoma in the US in 2023 and 2033
  • Figure 32: Sales forecast by class for glaucoma in the 5EU in 2023 and 2033
  • Figure 33: Sales forecast by class for glaucoma in Japan in 2023 and 2033
目次
Product Code: GDHC299PIDR-7M

This report covers the 7MM (US, France, Germany, Italy, Spain, UK, Japan) and provides an Excel-based forecast model for the Glaucoma market through 2033.

According to GlobalData, 2023 sales of glaucoma therapeutics across the 7MM are estimated to be $2.1 billion. The market is projected to grow at a compound annual growth rate (CAGR) of 2.1%, reaching approximately $2.5 billion by 2033.

The major drivers of glaucoma market growth over the forecast period are -

  • A projected increase in the prevalence of glaucoma throughout the 7MM resulting from an aging population.
  • The launches of six pipeline agents in the US and Japan.
  • The anticipated launches of new products are expected to address unmet needs in the treatment of glaucoma.

These are the major barriers that will restrict the growth of the CKD market during the forecast period -

  • Several products are due to lose exclusivity within the forecast period, and the subsequent generic erosion represents a significant impediment to growth.
  • Poor adherence to therapy will continue to stymie the sales of topical glaucoma therapies throughout the forecast period.
  • The crowded and highly genericized nature of the glaucoma market represents significant competition for new therapies.

Scope

  • Overview of glaucoma, including epidemiology, symptoms, diagnosis, and disease management.
  • Annualized glaucoma therapeutics market revenue, cost of therapy per patient, and treatment usage patterns forecast from 2023 to 2033.
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and implications of these factors for the glaucoma therapeutics market.
  • Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for glaucoma treatment. The most promising candidates in late-stage development are profiled.
  • Analysis of the current and future market competition in the global glaucoma therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to Buy

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the 7MM glaucoma therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the 7MM glaucoma therapeutics market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table of Contents

Table of Contents

  • About GlobalData

1 Glaucoma: Executive Summary

  • 1.1 The glaucoma market will increase between 2023 and 2033.
  • 1.2 The development of drugs with novel MOAs or routes of administration marks a shift in glaucoma corporate strategy.
  • 1.3 Unmet needs remain for glaucoma, particularly improving patient compliance.
  • 1.4 Late-stage pipeline drugs entering the glaucoma market are poised to drive growth.
  • 1.5 What do physicians think?

2 Introduction

  • 2.1 Catalyst
  • 2.2 Related reports
  • 2.3 Upcoming reports

3 Disease Overview

  • 3.1 Etiology and pathophysiology
    • 3.1.1 Overview
    • 3.1.2 Etiology
    • 3.1.3 NTG
    • 3.1.4 Pathophysiology
  • 3.2 Classification or staging systems

4 Epidemiology

  • 4.1 Disease background
  • 4.2 Risk factors and comorbidities.
  • 4.3 Global and historical trends
  • 4.4 7MM forecast methodology
    • 4.4.1 Sources
    • 4.4.2 Forecast assumptions and methods
    • 4.4.3 Forecast assumptions and methods: diagnosed prevalent cases of POAG (excluding NTG)
    • 4.4.4 Forecast assumptions and methods: diagnosed prevalent cases of NTG.
    • 4.4.5 Forecast assumptions and methods: diagnosed prevalent cases of PACG
    • 4.4.6 Forecast assumptions and methods: diagnosed incident cases of acute PACG.
    • 4.4.7 Forecast assumptions and methods: diagnosed prevalent cases of secondary glaucoma.
  • 4.5 Epidemiological forecast for glaucoma (2023-33)
    • 4.5.1 Diagnosed prevalent cases of POAG (excluding NTG)
    • 4.5.2 Age-specific diagnosed prevalent cases of POAG (excluding NTG)
    • 4.5.3 Sex-specific diagnosed prevalent cases of POAG (excluding NTG)
    • 4.5.4 Diagnosed prevalent cases of NTG
    • 4.5.5 Diagnosed prevalent cases of PACG.
    • 4.5.6 Age-specific diagnosed prevalent cases of PACG
    • 4.5.7 Sex-specific diagnosed prevalent cases of PACG
    • 4.5.8 Diagnosed prevalent cases acute and chronic PACG
    • 4.5.9 Diagnosed incident cases of acute PACG
    • 4.5.10 Diagnosed incident cases of secondary glaucoma
  • 4.6 Discussion
    • 4.6.1 Epidemiological forecast insight
    • 4.6.2 COVID-19 impact.
    • 4.6.3 Limitations of the analysis
    • 4.6.4 Strengths of the analysis

5 Disease Management

  • 5.1 Diagnosis overview
    • 5.1.1 Ophthalmoscopy
    • 5.1.2 Tonometry
    • 5.1.3 Perimetry
    • 5.1.4 Pachymetry
    • 5.1.5 Gonioscopy
  • 5.2 Treatment overview
    • 5.2.1 Treatment guidelines
  • 5.3 KOL insights on disease management

6 Current Treatment Options

  • 6.1 Overview

7 Unmet Needs and Opportunity Assessment

  • 7.1 Overview
  • 7.2 Improved patient compliance
  • 7.3 Treatments with better IOP lowering-ability
  • 7.4 Novel drug delivery systems
  • 7.5 Neuroprotective drugs
  • 7.6 Improved diagnosis and monitoring

8 R&D Strategies

  • 8.1 Overview
    • 8.1.1 New IOP-lowering drugs
    • 8.1.2 Implants in glaucoma
  • 8.2 Clinical trials design
    • 8.2.1 Clinical endpoints for glaucoma
    • 8.2.2 Inclusion and exclusion criteria

9 Pipeline Assessment

  • 9.1 Overview
  • 9.2 Promising drugs in clinical development

10 Pipeline Valuation Analysis

  • 10.1 Overview
  • 10.2 Competitive assessment

11 Current and Future Players

  • 11.1 Overview
  • 11.2 Deal-making trends

12 Market Outlook

  • 12.1 Global markets
    • 12.1.1 Forecast
    • 12.1.2 Drivers and barriers - global (7MM) issues
  • 12.2 US
    • 12.2.1 Forecast
    • 12.2.2 Key events
    • 12.2.3 Drivers and barriers
  • 12.3 5EU
    • 12.3.1 Forecast
    • 12.3.2 Key events
    • 12.3.3 Drivers and barriers
  • 12.4 Japan
    • 12.4.1 Forecast
    • 12.4.2 Key events
    • 12.4.3 Drivers and barriers

13 Appendix

  • 13.1 Bibliography
  • 13.2 Abbreviations
  • 13.3 Methodology
    • 13.3.1 Forecasting methodology
  • 13.4 Primary research - KOLs interviewed for this report.
    • 13.4.1 KOLs
  • 13.5 Primary research - prescriber survey
  • 13.6 About the authors
    • 13.6.1 Analyst
    • 13.6.2 Therapy Area Director
    • 13.6.3 Epidemiologist
    • 13.6.4 Reviewers, epidemiology
    • 13.6.5 Vice President of Disease Intelligence and Epidemiology
    • 13.6.6 Global Head of Pharma Research, Analysis, and Competitive Intelligence
  • Contact Us